Rasio utang jangka dawa marang modal NexImmune Corporation (NEXI)

NexImmune, Inc. (NEXI) focused its operations on discovering methods for T-cell activation and securing funding from pharmaceutical behemoths. However, following the failure of drug trials, the company liquidated its laboratories, and its standalone debt stands at 0.00. This price chart clearly demonstrates the consequences of this collapse. Meanwhile, the business as a whole exhibited high resilience to macroeconomic shocks and remained independent of seasonal market fluctuations.

NexImmune, Inc. (NEXI) is currently focusing on the monetization of intellectual property rights following the cessation of clinical trials. The current value of 0.00 reflects the ratio of long-term liabilities to equity under a liquidation model. This metric measures the share of loans with a maturity of over one year, determining the business's financial stability. A low debt load minimizes the risk of bankruptcy in the absence of revenue. Analysis of the long-term financial dependency ratio allows for an assessment of the assets' margin of safety.